ARSK

Across TCGA pan-cancer cohorts, ARSK Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ARSK data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher ARSK Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARSK expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, HNSC, and SARC are the cancer types where ARSK Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.241	0.743	<.001	32	view →
HNSC	OS	Median	II,III,IV	0.266	0.674	.008	31	view →
SARC	DFS	Median	All	0.037	0.632	<.001	12	view →
THCA	DFS	Median	All	0.133	0.842	.009	9	view →
LUAD	DFS	Median	II,III,IV	0.178	0.721	.008	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	DFS	Median	All	0.962	0.830	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ARSK–SKCM (DFS)

Open the SKCM breakdown →